News & Updates

Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.

Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.

A distinct community and greater heterogeneity have been observed in the plasma microbiome compared to the gut in both patients with systemic lupus erythematosus (SLE) and healthy individuals, reports a recent study. This suggests that the predominant circulating microbiome may originate from sites other than the gastrointestinal tract.

Patients with gout who refuse to take allopurinol for their condition do so because of their desire to lead a normal life and to test whether they could reduce the dose without experiencing any symptoms, a recent study has found.

The risks of sudden cardiac arrest or ventricular arrythmia (SCA/VA) and major adverse cardiovascular event (MACE) are comparable between methotrexate (MTX) and hydroxychloroquine (HCQ) in older patients with rheumatoid arthritis (RA), reports a study.

Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.